Delhi sees dip in COVID-19 cases, Centre can allocate extra oxygen to needy states: Manish Sisodia
Sisodia also said that Delhi s oxygen requirement has also reduced to 582 MT per day from over 700 MT earlier. The central government can reroute the additional oxygen being supplied to Delhi to other states, he said
BusinessToday.In | May 13, 2021 | Updated 14:22 IST
Delhi Deputy CM Manish Sisodia, in an SOS to the Centre on Wednesday, said Bharat Biotech has declined to supply any more vaccines to the national capital
Amid the vaccine crisis in the national capital, Delhi deputy chief minister shared the good news with the people on Thursday. He said Delhi s case positivity rate has gone down to 14 per cent lowest in nearly a month as Covid-19 cases see a decline. He also said with this, Delhi s oxygen requirement has also reduced to 582 MT per day from over 700 MT earlier. The central government can reroute the additional oxygen being supplied to Delhi to other states, he sa
A spate of downgrades last year had already left India s investment grade credit ratings hanging by a thread and the severity of the current virus wave is making S&P, Moody s and Fitch agitated again
Read more about Torrent Pharma inks pact with Eli Lilly for Covid drug Baricitinib in India on Business Standard. Under royalty-free, non-exclusive deal, Torrent can make and sell baricitinib in India along with the US firm s other license partners
Torrent Pharma enters into Voluntary Licensing Agreement with Lilly for Baricitinib for Covid-19 in India equitybulls.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from equitybulls.com Daily Mail and Mail on Sunday newspapers.
Shares of pharmaceutical companies were on a roll at the bourses on Monday, with the Nifty Pharma index hitting an all-time high of 14,172, after rising 3 per cent on the National Stock Exchange (NSE) on the back of strong rally in stocks like Sun Pharmaceutical Industries, Torrent Pharma, Alkem Laboratories, Divis Laboratories, Lupin and Dr Reddys Laboratories. The pharma index surpassed its previous high of 14,020.70, touched in intra-day trade on April 7, 2015.
Since April, the Nifty Pharma index has outperformed the market by surging 15 per cent, against 1.7 per cent gain in the Nifty50 index. In the past one month, the market values of Cadila Healthcare, Lupin, Dr Reddys Laboratories, Divis Laboratories, Aurobindo Pharma and Sun Pharma have appreciated between 10 per cent and 21 per cent. In comparison, the benchmark index was up less than 1 per cent in that the period.